We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
The Number of Vaccines Trials (2016)
Vaccine Strategies in Clinical Trials (2016)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Number of Broadly Neutralizing Antibodies Discovered
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Vaccines Clinical Trial Participants by Region
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
New HIV Infections by Region (2014)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Epidemics Successfully Combated with Vaccines (From 1980)
We know that an Vaccines will be an important part of a long-term strategy to end the HIV/AIDS epidemic. The road ahead is long, but a vaccines is possible. Clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Global Investment in Vaccines R&D (2014)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
HIV Vaccine Research: An Update
A quick, colorful and comprehensive overview of HIV vaccine research. Four pages, five top-line updates, this is a speedy read, designed to give a sense of the momentum and major issues coming up in the year to come.
Second European HIV Prevention Summit Meeting Report
In January 2016, the European AIDS Treatment Group (EATG) and AVAC jointly convened the second European HIV Prevention Summit in Brussels. This meeting brought pharmaceutical companies, public health experts, academics and leading scientists in the field of prevention research together with over 50 European community-based advocates for three days of information exchange and debate. The four-page executive summary is attached. The meeting agenda and slide presentations from the meeting are available for download at http://eatgavacprevention.tumblr.com.
Px Wire April-June 2016, Vol. 9, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue is an advocate’s guide to the past, present and future of the dapivirine ring for HIV prevention. Featuring a timeline of key milestones that could lead to licensure, a simple comprehensive Q & A, and a closer look at where sub-Saharan African women will have access to daily oral PrEP and/or the Ring via open-label extension studies.